Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648505 | Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg | PHASE1 | COMPLETED | 36 | — | — | Jun 1, 2005 | Jun 1, 2005 | Apr 24, 2024 | 1 | United States |
| NCT00649454 | Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg | PHASE1 | COMPLETED | 36 | — | — | Jun 1, 2005 | Jun 1, 2005 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Glipizide and Metformin HCl Tablets 5 mg/500 mg |
| 2 | ACTIVE_COMPARATOR | Metaglip® Tablets 5 mg/500 mg |
| Name | Type | Description |
|---|---|---|
| Glipizide and Metformin HCl Tablets 5 mg/500 mg | DRUG | 5/500mg, single dose fed |
| Metaglip® Tablets 5 mg/500 mg | DRUG | 5/500mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older 2. Sex: Male and/or non-pregnant, non-lactating female a. Women of childbearing potential must have a negative serum (β-HCG) pregnancy test performed within 21 days prior to the start of the study and on the evening prior to each dose administration. I...